These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 14585938

  • 1. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.
    Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, Peters GR, Roth AW, McElhattan J, Colwell CW, EXULT A Study Group.
    N Engl J Med; 2003 Oct 30; 349(18):1703-12. PubMed ID: 14585938
    [Abstract] [Full Text] [Related]

  • 2. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.
    Schulman S, Wåhlander K, Lundström T, Clason SB, Eriksson H, THRIVE III Investigators.
    N Engl J Med; 2003 Oct 30; 349(18):1713-21. PubMed ID: 14585939
    [Abstract] [Full Text] [Related]

  • 3. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
    Eriksson BI, Arfwidsson AC, Frison L, Eriksson UG, Bylock A, Kälebo P, Fager G, Gustafsson D.
    Thromb Haemost; 2002 Feb 30; 87(2):231-7. PubMed ID: 11858482
    [Abstract] [Full Text] [Related]

  • 4. Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty.
    Colwell CW, Berkowitz SD, Lieberman JR, Comp PC, Ginsberg JS, Paiement G, McElhattan J, Roth AW, Francis CW, EXULT B Study Group.
    J Bone Joint Surg Am; 2005 Oct 30; 87(10):2169-77. PubMed ID: 16203879
    [Abstract] [Full Text] [Related]

  • 5. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial.
    Francis CW, Davidson BL, Berkowitz SD, Lotke PA, Ginsberg JS, Lieberman JR, Webster AK, Whipple JP, Peters GR, Colwell CW.
    Ann Intern Med; 2002 Oct 15; 137(8):648-55. PubMed ID: 12379064
    [Abstract] [Full Text] [Related]

  • 6. Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran.
    Eriksson H, Lundström T, Wåhlander K, Clason SB, Schulman S, THRIVE III Investigators.
    Thromb Haemost; 2005 Sep 15; 94(3):522-7. PubMed ID: 16268466
    [Abstract] [Full Text] [Related]

  • 7. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.
    Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Mouret P, Rosencher N, Eskilson C, Nylander I, Frison L, Ogren M, METHRO III Study Group.
    Thromb Haemost; 2003 Feb 15; 89(2):288-96. PubMed ID: 12574809
    [Abstract] [Full Text] [Related]

  • 8. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study.
    Heit JA, Colwell CW, Francis CW, Ginsberg JS, Berkowitz SD, Whipple J, Peters G, AstraZeneca Arthroplasty Study Group.
    Arch Intern Med; 2001 Oct 08; 161(18):2215-21. PubMed ID: 11575978
    [Abstract] [Full Text] [Related]

  • 9. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C, Mouret P.
    Semin Vasc Med; 2005 Aug 08; 5(3):266-75. PubMed ID: 16123914
    [Abstract] [Full Text] [Related]

  • 10. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial.
    Fiessinger JN, Huisman MV, Davidson BL, Bounameaux H, Francis CW, Eriksson H, Lundström T, Berkowitz SD, Nyström P, Thorsén M, Ginsberg JS, THRIVE Treatment Study Investigators.
    JAMA; 2005 Feb 09; 293(6):681-9. PubMed ID: 15701909
    [Abstract] [Full Text] [Related]

  • 11. A review of the oral direct thrombin inhibitor ximelagatran: not yet the end of the warfarin era..
    Mohapatra R, Tran M, Gore JM, Spencer FA.
    Am Heart J; 2005 Jul 09; 150(1):19-26. PubMed ID: 16084146
    [Abstract] [Full Text] [Related]

  • 12. Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran.
    Harenberg J, Ingrid J, Tivadar F.
    Isr Med Assoc J; 2002 Nov 09; 4(11):1003-5. PubMed ID: 12489490
    [Abstract] [Full Text] [Related]

  • 13. Melagatran and ximelagatran: new drug. No real simplification of anticoagulant therapy.
    Prescrire Int; 2005 Aug 09; 14(78):127-32. PubMed ID: 16106594
    [Abstract] [Full Text] [Related]

  • 14. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V).
    Halperin JL, Executive Steering Committee, SPORTIF III and V Study Investigators.
    Am Heart J; 2003 Sep 09; 146(3):431-8. PubMed ID: 12947359
    [Abstract] [Full Text] [Related]

  • 15. Ximelagatran for the secondary prevention of venous thromboembolism: a complementary follow-up analysis of the THRIVE III study.
    Schulman S, Lundström T, Wålander K, Billing Clason S, Eriksson H.
    Thromb Haemost; 2005 Oct 09; 94(4):820-4. PubMed ID: 16270637
    [Abstract] [Full Text] [Related]

  • 16. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
    Douketis JD, Arneklev K, Goldhaber SZ, Spandorfer J, Halperin F, Horrow J.
    Arch Intern Med; 2006 Apr 24; 166(8):853-9. PubMed ID: 16636210
    [Abstract] [Full Text] [Related]

  • 17. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.
    Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, Cushman M, Moll S, Kessler CM, Elliott CG, Paulson R, Wong T, Bauer KA, Schwartz BA, Miletich JP, Bounameaux H, Glynn RJ, PREVENT Investigators.
    N Engl J Med; 2003 Apr 10; 348(15):1425-34. PubMed ID: 12601075
    [Abstract] [Full Text] [Related]

  • 18. Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery.
    Evans HC, Perry CM, Faulds D.
    Drugs; 2004 Apr 10; 64(6):649-78. PubMed ID: 15018597
    [Abstract] [Full Text] [Related]

  • 19. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
    Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG, RECORD3 Investigators.
    N Engl J Med; 2008 Jun 26; 358(26):2776-86. PubMed ID: 18579812
    [Abstract] [Full Text] [Related]

  • 20. Ximelagatran for treatment and prophylaxis of recurrent events in deep vein thrombosis.
    Koscielny J, Kiesewetter H, Jörg I, Harenberg J.
    Clin Appl Thromb Hemost; 2007 Jul 26; 13(3):299-307. PubMed ID: 17636192
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.